Press – Maiwald

Press Coverage

5 Dec 2025 -

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement.

Royalty Pharma and Denali have entered into a $275 million financing agreement which, pursuant to a synthetic royalty agreement, is based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle™-enabled enzyme rep...

25 Aug 2025 -

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...

14 Jul 2025 -

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

Maiwald press releases

9 Jul 2025 - Press Release

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

17 Jun 2025 - Press Release

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the EPO Board of Appeal confirmed the revocation of European Patent EP 2 252 148 following the wit...

25 Mar 2025 - Press Release

Roche gets Illumina unit’s DNA testing patent revoked

A European Patent Office board of appeal said in a ruling published on March 10th that Roche Diagnostics GmbH proved Verinata Health Inc.'s blueprint lacks an inventive step over an earlier international patent application setting out a similar way of testing "free-floating ...

All press releases

Maiwald in the press

Press Coverage

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement.

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Maiwald press releases

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

Roche gets Illumina unit’s DNA testing patent revoked

Press Contact

Dr. Eva Dörner